Disaggregation of Alzheimer beta-amyloid by site-directed mAb. - Wikidata - wikimedia - TriplyDB

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

http://www.wikidata.org/entity/Q36109944

about

Clinical immunologic approaches for the treatment of Alzheimer's disease Immunotherapy as treatment for Alzheimer’s disease Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease Active and passive immunotherapy for neurodegenerative disorders The immunotherapy of Alzheimer's disease Immunotherapy for Alzheimer's disease: hoops and hurdles Tau-targeted treatment strategies in Alzheimer's disease CD4 T cells in immunity and immunotherapy of Alzheimer's disease Molecular basis for passive immunotherapy of Alzheimer's disease Stabilization of a -hairpin in monomeric Alzheimer's amyloid- peptide inhibits amyloid formation Structures of Aβ-Related Peptide−Monoclonal Antibody Complexes ,Immunotherapeutic approaches for Alzheimer's disease Disease modifying therapies for Alzheimer's disease targeting Aβ oligomers: implications for therapeutic mechanisms An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease.Energy landscapes of the monomer and dimer of the Alzheimer's peptide Abeta(1-28).Amelioration of amyloid load by anti-Abeta single-chain antibody in Alzheimer mouse model Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils.Exceptional amyloid beta peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds.Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease Clinical applications of a peptide-based vaccine for glioblastoma.Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine.EGFRvIII-targeted vaccination therapy of malignant glioma.Modulation of amyloid beta protein precursor processing as a means of retarding progression of Alzheimer's disease Alzheimer's disease: is a vaccine possible?Amyloid-beta immunotherapy for Alzheimer's disease Conformational Abs recognizing a generic amyloid fibril epitope.Beta-amyloid therapies in Alzheimer's disease.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Cell therapy: a safe and efficacious therapeutic treatment for Alzheimer's disease in APP+PS1 mice Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits.Novel immunological approaches for the treatment of Alzheimer's disease.Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid β peptide.Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid.Physiopathological modulators of amyloid aggregation and novel pharmacological approaches in Alzheimer's disease.Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.Immunotherapy for Alzheimer's disease.Investigating interventions in Alzheimer's disease with computer simulation models Immunological approaches as therapy for Alzheimer's disease.

P2860

Q22241380-63D332B0-461E-40A8-9544-311890FFF075 Q22241491-BA6FA6D3-26DB-4368-8BC2-97954D2D9584 Q24534813-BCD7EC3C-3BE5-433E-9CC6-0AC4BF602D0B Q24657879-0DCB5EC6-E894-430B-82EC-B9C26A9EC019 Q24804900-E6810F85-4E4B-4F83-A0C7-8E73AFEA0EB3 Q26823877-D72EF84A-9FED-4739-94AE-DF660B8781C1 Q27023429-3B16A5FC-9247-44CA-9D9F-A34EC2BA0D30 Q27024202-BEBC1EE9-5FD2-4EA2-97A4-076DC95A22C7 Q27648521-6F04C59E-9A56-4BD4-90D2-23A2698A468C Q27650192-F88B9288-E7CE-4A7F-951F-1D67C44D7207 Q27655072-17865FBC-ED24-444C-98E3-93877DA5207A Q28081278-5420DC6D-4FE7-4AF1-9188-A75305633B3B Q28680809-5DB18F5E-0B79-41F5-B72E-ACE0B962C0CF Q30316057-A3993B83-4697-44CA-B61C-3B5883356A3A Q30478932-37EC7D7D-2E16-44D7-A210-DD52F0853C09 Q31151076-62223A4D-569A-4165-9F74-A2E5CA4E2191 Q33240688-CF938B57-27D3-43CF-AF6A-BF207B091F5E Q33307478-7C54D704-5AC3-4807-BD31-5419B52E9B49 Q33381465-4FC3F51A-B22D-4035-8E2D-D29D0FE2E4DF Q33392254-7FB20E3A-DF03-4BE5-92AF-E39CACA70136 Q33624303-D4066375-9DDF-408B-A103-1BEC26E0E176 Q33668575-76ED745D-1F97-4B62-B6B4-3C82C6FE56CA Q33742312-25BF6EF4-782C-4D77-9F23-1F86092E8D3A Q33758459-D2A38696-F354-41BC-95BB-5C7479010FF7 Q33773936-867838C4-D7CB-4043-9FDC-B3E138410314 Q33861011-907C94BA-547C-4D0A-9B39-715BC01D2387 Q33954737-8122358D-A156-490D-892A-77C5F8C30808 Q34009881-39FF0D4D-7C41-4338-9925-5C7E5EAC4642 Q34204313-3F297E21-3C81-40A6-9245-B6D8AF5382CF Q34376103-DB83CA0F-133E-43BE-8FFC-6DD29AB17454 Q34506405-1B6D4032-EA04-4F5A-8D9D-5FA7BC72D647 Q34553059-301A7733-E7D9-45C3-9F26-0DF7F17D444C Q34562675-C91BDB44-DA72-4282-B4A6-827CBB000209 Q34574825-2309BFEB-1F96-4BC8-AB55-010C30D8EBE4 Q34698382-E286B6BB-DD38-4A51-99B9-6F328EE2334F Q34721350-F66C9151-1C95-40D3-A3A3-6801E5A01B01 Q34763076-71E2EB5C-3A41-4B12-BECB-CC76F2320509 Q34783722-6335CDCF-478F-405C-A6BD-D66F34299669 Q35009820-4652B10D-A0C5-4082-BC6B-030EC2BDFA50 Q35040852-E1E8C8EF-66A3-45A8-B2A6-6EA9590C77CF

P2860

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

http://www.wikidata.org/entity/Q36109944

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@ast

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@en

type

label

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@ast

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@en

prefLabel

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@ast

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@en

P1433

Q36109944-A00338CD-5670-4C9C-B396-DA7217D0FD83

P1476

Q36109944-6848432E-24BC-408E-B914-710A15D3FB75

P2093

Q36109944-06BEEF89-6283-4336-B352-46B98C2DC7E1

Q36109944-3EDA0293-DF72-458D-B401-029F8FE44CF8

Q36109944-D5120E20-D4A2-41DC-AE72-53A57CE49575

Q36109944-F84F0F5D-6D17-41F6-87D0-8DB0497CCBB2

P2860

Q36109944-10491F77-33A7-4280-B2D3-0D07B69D09B1

Q36109944-160A060E-6310-40A9-A4C5-7043B99E710C

Q36109944-18098490-9667-4367-98F5-FA7B62D56851

Q36109944-1A6BCEC2-B85D-4581-AFB3-5B3BA32AEBBE

Q36109944-1D39E6F9-88BE-467E-AD4A-C7B7B98894B5

Q36109944-1E6EACE3-F7E7-4582-B39D-A1829DE94E69

Q36109944-214D142A-9A97-4AC7-8632-D6282245DBC3

Q36109944-335ADCC4-E941-4450-894D-CE6DFF665243

Q36109944-3BE2E211-1268-439D-8513-9401BBD2C991

Q36109944-3C249E57-ECF7-4A2A-B1BF-27DDFD3C171F

P304

Q36109944-805FD36D-EE36-43D5-A04B-7F88527DE4AC

P31

Q36109944-CBC8B199-E1B6-41B6-B9A9-19A3FB3EDA3D

P356

Q36109944-C37F5E9F-2ACB-4572-8274-F93A670138C1

P407

Q36109944-5909BDA6-CBFB-4DC9-BBE9-978D13283CD6

P433

Q36109944-7EAB70AA-10B4-44C4-8FA7-73E1228CFC53

P478

Q36109944-FA7E9D6F-4153-44FC-88E1-81199256BB4B

P577

Q36109944-4CBC9B08-36B0-4558-A184-EDA3EF4A1E18

P5875

Q36109944-FF62474D-F280-41A8-A05F-B1105FCC8D48

P698

Q36109944-155BF7E4-8D1A-4EF9-A126-B0031F33E891

P921

Q36109944-2694FDA9-8B58-41D8-B35E-EA06F2E9030E

P932

Q36109944-65CFB218-D7FD-4F66-A0C1-F18CED2DA38E

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

@en

P2093

B Solomon

http://www.w3.org/2001/XMLSchema#string

D Frankel

http://www.w3.org/2001/XMLSchema#string

E Hanan-Aharon

http://www.w3.org/2001/XMLSchema#string

R Koppel

http://www.w3.org/2001/XMLSchema#string

P2860

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides

Interactions of protein antigens with antibodies.

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

Structure of beta-crystallite assemblies formed by Alzheimer beta-amyloid protein analogues: analysis by x-ray diffraction.

Temperature-dependent X-ray diffraction as a probe of protein structural dynamics.

Molecular dynamics simulations in biology.

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro

Partly native epitopes are already present on early intermediates in the folding of tryptophan synthase.

Morphology and antibody recognition of synthetic beta-amyloid peptides.

P304

4109-4112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.94.8.4109

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

1997-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14109912

http://www.w3.org/2001/XMLSchema#string

P698

9108113

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

20576

http://www.w3.org/2001/XMLSchema#string